Skip to content
Donate
Membership
Contact
  • About

    About

    The peak professional body for childhood cancer across Australia and New Zealand.

    Learn More

    Menu

    • About ANZCHOG
    • Board of Directors
    • Our People
    • Our Network
    • Supporters & Partners
    • Position Statements & Guidelines
  • Clinical Trials
    Total Trials
    60
    Open Trials
    26
    Preparing to Open
    3
    Temp. Closed
    3
    Closed
    21
    Complete
    7

    Menu

    • Our Trials
    • Children's Clinical Cancer Clinical Trials Repository
    • Childhood Cancer
  • Resource SPACE
    Document/ PDF

    Supporting parents making clinical trial decisions for their child

    Behavioural Sciences Unit – Delta Study
    Document/ PDF

    Should my child participate in a clinical trial

    Center for Information and Study on Clinical Research Participation (CISCRP)

    Menu

    • Visit SPACE
    • Videos
    • Documents
    • Podcasts
  • Major Projects
    • July 2, 2025

    Getting to know CoACT in Brain Cancer Awareness Month

    • childhoodcancer, clinical trials, Paediatric Brain Cancer
    • February 6, 2025

    Australian Government invests $14 million in ANZCHOG-led childhood brain cancer initiative

    • childhoodcancer, clinical trials, Paediatric Brain Cancer

    Menu

    • CoACT
    • Equitable Pathways
    • CIRCCA
    • Optimal Care Pathways
  • Annual Scientific Meeting

     Innovate, Integrate, Inspire:   Elevating Supportive Care in Paediatric Haematology and Oncology  

    Learn More

    Menu

    • 2026 Newcastle
    • Program
    • Speakers
    • Accommodation
  • News & Events
    • Featured, PaedNeoVax, Trial Update
    • November 5, 2026

    PaedNeoVax Clinical Trial Opens to Target Aggressive Childhood Brain Tumours

    Menu

    • Latest News
    • Upcoming Events

    8–11 September 2027

    SIOP 2027

  • About Us
    • ANZCHOG
    • Board of Directors
    • Our People
    • Our Network
    • Collaborators, Supporters & Partners
  • Clinical Trials
    • Clinical Trials
    • ANZCHOG Children’s Cancer Clinical Trials Repository
    • Childhood Cancer
  • Major Projects
    • CIRCAA
    • CoACT
    • Equitable Pathways
    • Optimal Care Pathways
  • Resource Space
  • Membership
  • Annual Scientific Meeting
Membership
Donate
Contact
Closed to RecruitmentPhase 0

Blinatumomab in Infant ALL (BlinFant)

A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)

View on registry →Registry IDs: ACTRN12620000542998

This study will investigate the effectiveness of the introduction of a new drug Blinotumomab to the standard treatment for infants diagnosed with acute lymphoblastic leukaemia (ALL). Blinotumomab attaches to the cancer cells, causing them to break down and die. Infants will be given the standard chemotherapy treatment for the first month, followed by an additional month of continuous treatment with Blinotumomab. This will require an extra period of hospitalisation.

The patient will have been treated according to the Interfant-06 protocol where they will have received standard induction therapy. If the patient is eligible for the current study, blinatumomab will be added to standard arm (1B) of the Interfant-06 protocol. The patient will receive 1 course of blinatumomab. The blinatumomab course (15 micrograms/m2/day) consists of a 4-week continuous intravenous infusion. The patient will be closely monitored during the first 72 hours of treatment and will be admitted to the hospital preferably for the full 4 weeks of the blinatumomab infusion with a minimum admission of 7 days. Following treatment with blinatumomab, the patient wil lrecommence standard treatment according to Interfant-06 (protocol 1B).

Site Status
Queensland Children's Hospital (QLD) Closed to Recruitment
Royal Children's Hospital (VIC) Closed to Recruitment
Children's Hospital at Westmead (NSW) Closed to Recruitment
Preparing to openOpenClosedComplete
Diagnosis StageNewly Diagnosed
National SponsorANZCHOG
Open Date20/07/2018
ConditionsAcute Lymphoblastic Leukaemia (ALL)
Patient RangeUp to < 1 year
05099+
Disease TypeLeukaemia / Lymphoma / Blood Disorders
Study TypeInterventional
International SponsorPrincess Maxima Center for paediatric Oncology & Utrecht

Funders

ANZCHOG acknowledges the valuable support of Blinatumomab in Infant ALL (BlinFant) by:

Cancer Australia

Media & Publication Highlights

Last updated 10 November 2026

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

Great! We’ve received your information.

We couldn’t process your submission. Please retry

  • Terms Of Use
  • Privacy Policy
  • Terms Of Use
  • Privacy Policy
  • Resource Hub
  • Childhood Cancer
  • What We Do
  • Resource Hub
  • Childhood Cancer
  • What We Do
  • Our Trials
  • Our Network
  • Position Statements & Guidelines
  • Our Trials
  • Our Network
  • Position Statements & Guidelines

Email
info@anzchog.org

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

Copyright © 2026 ANZCHOG - All Rights Reserved

Linkedin-in